Skip to main content

Horizon Discovery, Mirna Collaborate on miRNA Mimics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mirna Therapeutics will test the effect of its proprietary miRNA mimics on a panel of Horizon Discovery's human isogenic cancer cell models, under a collaboration announced today.

Under the deal, Horizon's X-Man human discovery cell lines will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna's miRNA mimics.

The project is being funded partly by a Cancer Prevention and Research Institute of Texas commercialization grant. Other terms of the deal were not disclosed.

In a statement, Paul Lammers, president and CEO of Mirna, said the partnership will "increase the understanding of how our highly potent tumor suppressor miRNA mimics act under human cancer cells characterized by different disease-causing mutations," which in turn will help the company to better define the best patient population for clinical trials.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.